永安藥業(002365.SZ):子公司取得實用新型專利及發明專利證書
格隆匯 11 月 3日丨永安藥業(002365.SZ)公佈,近日,公司控股子公司湖北凌安科技有限公司(“凌安科技”)收到中華人民共和國國家知識產權局頒發的實用新型專利證書,以及取得一項發明專利證書,實用新型名稱:一種減水劑原材料的自動噴刮制粉系統,發明名稱:一種磺化廢棄聚苯乙烯泡沫塑料高性能減水劑的製備方法。
控股子公司凌安科技一直致力於聚羧酸減水劑及所有聚醚的技術研發及應用,上述實用新型專利和發明專利的取得有利於凌安科技充分發揮自主知識產權優勢,不斷進行技術創新,促進凌安科技在聚醚及聚羧酸減水劑領域保持技術領先優勢,不斷提升其核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.